Manejo de las inyecciones intravítreas

  1. F. Gómez-Ulla
  2. E. Basauri
  3. L. Arias
  4. F. Martínez-Sanz
Revista:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Año de publicación: 2009

Volumen: 84

Número: 8

Páginas: 377-388

Tipo: Artículo

DOI: 10.4321/S0365-66912009000800003 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Archivos de la Sociedad Española de Oftalmologia

Resumen

Objetivo: La inyección intravítrea es una técnica mínimanente invasiva de demostrada eficacia en el tratamiento de numerosas enfermedades vitreorretinianas. Su uso, gracias a nuevas medicaciones e indicaciones, se ha generalizado en los últimos años. La práctica de esta técnica sin las precauciones adecuadas, puede causar complicaciones graves, en especial la infección. La finalidad de esta Guía es difundir entre los oftalmólogos un compendio de recomendaciones estandarizadas que faciliten la administración de inyecciones intravítreas, con las máximas medidas de seguridad y fiabilidad. Método: Se efectúa: 1. Una revisión bibliográfica de la evidencia científica publicada hasta la fecha. 2. Consulta de práctica clínica habitual entre especialistas con experiencia acreditada. 3. Contraste de nuestra información con la contenida en las guías publicadas en otros países. Resultado: Aunque no hay un consenso absoluto, las maniobras recomendadas en esta Guía parecen, hasta el día de la fecha, las más adecuadas para minimizar los riesgos de complicaciones, en especial la infección. Se consideran de particular importancia la antisepsis con povidona yodada, el uso de guantes y materiales estériles y una técnica adecuada de inyección. Conclusiones: Series muy grandes de inyecciones intravitreas realizadas en consulta y aplicando las medidas aquí recomendadas, presentan una incidencia muy baja de complicaciones, en especial la sospecha de infección intraocular.

Referencias bibliográficas

  • Ohm, J. (1911). Über die Behandlung der Netzhautablo¨sung durch operative Entleerung der subretinalen Flössigkeit und Einspritzung von Luft in den Glaskörper. Albrecht von Graefes Arch Ophthalmol. 79. 442-450
  • Rycroft, B. (1945). Penicillin and the control of deep intraocular infection. Br J Ophthalmol. 29. 57-87
  • Schneider, J, Frankel, SS. (1947). Treatment of late postoperative intraocular infections with intraocular injection of penicillin. Arch Ophthalmol. 37. 304-307
  • Rosengren, B. (1952). 300 cases operated upon for retinal detachment; method and results. Acta Ophthalmol (Copenh). 30. 117-122
  • Cibis, PA, Becker, B, Okun, E, Canaan, S. (1962). The use of liquid silicone in retinal detachment surgery. Arch Ophthalmol. 68. 590-599
  • Domínguez Collazo, A, Fonseca Sandomingo, A, Gómez Montaña, J. (1985). Cirugía precoz y ambulatoria del desprendimiento de retina. Arch Soc Esp Oftalmol. 48. 47-54
  • Dominguez, A. (1995). Pneumocasis. IDIOSA. Madrid.
  • Forster, RK, Zachary, IG, Cottingham, AJ Jr, Norton, EW. (1976). Further observations on the diagnosis, cause, and treatment of endophthalmitis. Am J Ophthalmol. 81. 52-56
  • Peyman, GA, Vastine, DW, Raichand, M. (1978). Experimental aspects and their clinical application. Ophthalmology. 85. 374-385
  • Henry, K, Cantrill, H, Fletcher, C, Chinnock, BJ, Balfour, HH Jr. (1987). Use of intravitreal ganciclovir (dihydroxy propoxymethyl guanine) for cytomegalovirus retinitis in a patient with AIDS. Am J Ophthalmol. 103. 17-23
  • Vitravene injection (fomivirsen sodium intravitreal injectable). US Food and Drug Administration.
  • Dominguez, A, Quiroga, P, Jareño, M. (1993). El tratamiento de enfermedades médicas con triamcinolona intravítrea. Arch Soc Esp Oftalmol. 65. 491-498
  • Domínguez, A. (1994). Dispositivos y medicamentos introducidos intraocularmente para el tratamiento en el consultorio de enfermedades de los ojos. An Real Acad Nac Med. 61. 377-385
  • Martidis, A, Duker, JS, Greenberg, PB, Rogers, AH, Puliafito, CA, Reichel, E. (2002). Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 109. 920-927
  • Greenberg, PB, Martidis, A, Rogers, AH, Duker, JS, Reichel, E. (2002). Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol. 86. 247-248
  • Antcliff, RJ, Spalton, DJ, Stanford, MR, Graham, EM, Ffytche, TJ, Marshall, J. (2001). Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology. 108. 765-772
  • Young, S, Larkin, G, Branley, M, Lightman, S. (2001). Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol. 29. 2-6
  • Martidis, A, Duker, JS, Puliafito, CA. (2001). Intravitreal triamcinolone for retinochoroidopathy. Arch Ophthalmol. 119. 1380-1383
  • Scott, IU, Flynn, HW Jr, Rosenfeld, PJ. (2003). Intravitreal triamcinolone acetonide for idiopathic cystoid macular edema. Am J Ophthalmol. 136. 737-739
  • Gómez-Ulla, F, Marticorena, J, Alfaro, DV 3rd, Fernández, M, Méndez, ER, Rothen, M. (2006). Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr Diabetes Rev. 2. 99-112
  • (2002). Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina. 22. 143-152
  • (2003). Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology. 110. 979-986
  • Gragoudas, ES, Adamis, AP, Cunningham, ET Jr, Feinsod, M, Guyer, DR. (2004). Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 351. 2805-2816
  • Cunningham, ET Jr, Adamis, AP, Altaweel, M, Aiello, LP, Bressler, NM, D’Amico, DJ. (2005). A phase II randomized double-masked trial of pegaptanib, an antivascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 112. 1747-1757
  • Rosenfeld, PJ, Brown, DM, Heier, JS, Boyer, DS, Kaiser, PK, Chung, CY. (2006). Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 355. 1419-1431
  • Brown, DM, Kaiser, PK, Michels, M, Soubrane, G, Heier, JS, Kim, RY. (2006). Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 335. 1432-1444
  • Rosenfeld, PJ, Brown, DM, Heier, JS, Boyer, DS, Kaiser, PK, Chung, CY. (2006). Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 355. 1419-1431
  • Dhalla, MS, Shah, GK, Blinder, KJ, Ryan, EH Jr, Mittra, RA, Tewari, A. (2006). Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 26. 988-993
  • Yoganathan, P, Deramo, VA, Lai, JC, Tibrewala, RK, Fastenberg, DM. (2006). Visual improvement following intravitreal bevacizumab (avastin) in exudative age-related macular degeneration. Retina. 26. 994-998
  • Haritoglou, C, Kook, D, Neubauer, A, Wolf, A, Priglinger, S, Strauss, R. (2006). Intravitreal bevacizumab (avastin) therapy for persistent diffuse diabetic macular edema. Retina. 26. 999-1005
  • Jorge, R, Costa, RA, Calucci, D, Cintra, LP, Scott, IU. (2006). Intravitreal bevacizumab (avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina. 26. 1006-1013
  • Rosenfeld, PJ, Moshfeghi, AA, Puliafito, CA. (2005). Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 36. 331-335
  • Jager, RD, Aiello, LP, Patel, SC, Cunningham, ET Jr. (2004). Risks of intravitreous injection: a comprehensive review. Retina. 24. 676-698
  • Fung, AE, Rosenfeld, PJ, Reichel, E. (2006). The International Bevacizumab safety Surrey: using the Internet to assess drug safety Worldwide. Br J Ophthalmol. 90. 1344-1349
  • Wu, L, Martínez-Castellanos, MA, Quiroz-Mercado, H, Arevalo, JF, Berrocal, MH, Farah, ME. (2008). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol. 246. 81-87
  • Moshfeghi, AA. Rate of endophthalmitis after Anti-VGEF after intravitreal injection. Retina Today. 75-76
  • Pilli, S, Kotsolis, A, Spaide, RF, Slakter, J, Freund, KB, Sorenson, J. (2008). Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol. 145. 879-882
  • Quiroz-Mercado, H, Ustariz-González, O, Martinez-Castellanos, M, Covarrubias, P, Dominguez,, F, Sanchez-Huerta, V. (2007). Our Experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Semin Ophthalmol. 22. 109-125
  • Heier, JS, Antoszyk, AN, Pavan, PR, Leff, SR, Rosenfeld, PJ, Ciulla, TA. (2006). Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 113. 633-642
  • Westfall, AC, Osborn, A, Kuhl, D, Benz, MS, Mieler, WF, Holz, ER. (2005). Acute endophthalmitis incidence: Intravitreal triamcinolone. Arch Ophthalmol. 123. 1075-1077
  • Moshfeghi, DM, Kaiser, PK, Scott, IU, Sears, JE, Benz, M, Sinesterra, JP. (2003). Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol. 136. 791-796
  • Jonisch, J, Lai, JC, Deramo, VA, Flug, AJ, Fastenberg, DM. (2008). Increased incidence of sterile endophtahlmitis following itravitreal preserved triamcinolone. Br J Ophthalmol. 92. 1051-1054
  • Moshfeghi, AA, Scott, IU, Flynn, HW Jr, Puliafito, CA. (2004). Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol. 138. 489-492
  • Moshfeghi, DM, Kaiser, PK, Bakri, SJ, Kaiser, RS, Maturi, RK, Sears, JE. (2005). Presumed sterile endophthalmitis following intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging. 36. 24-29
  • Aiello, LP, Brucker, AJ, Chang, S, Cunningham, ET Jr, Damico, DJ, Flynn, HW Jr. (2004). Evolving guidelines for intravitreal injections. Retina. 24. 3-19
  • Jaissle, GB, Szurman, P, Bartz-Schmidt, KU. (2005). Empfehlung fur die Durcgfuhrung von intravitrealen Injektionen. Klin Monatsbl Augenheilkd. 222. 390-395
  • Intravitrel injections Procedure Guideline.
  • Speaker, MG, Milch, FA, Shah, MK, Eisner, W, Kreiswirth, BN. (1991). Role of external bacterial flora in the pathogenesis of acute postoperative endophthalmitis. Ophthalmology. 98. 639-650
  • Bannerman, TL, Rhoden, DL, McAllister, SK, Miller, JM, Wilson, LA. (1997). The source of coagulase-negative staphylococci in the Endophthalmitis Vitrectomy Study: A comparison of eyelid and intraocular isolates using pulsed-field gel electrophoresis. Arch Ophthalmol. 115. 357-361
  • Han, DP, Wisniewski, SR, Wilson, LA, Barza, M, Vine, AK, Doft, BH. (1996). Spectrum and susceptibilities of microbiologic isolates in the Endophthalmitis Vitrectomy Study. Am J Ophthalmol. 122. 1-17
  • Leong, JK, Shah, R, McCluskey, PJ, Benn, RA, Taylor, RF. (2002). Bacterial contamination of the anterior chamber during phacoemulsification cataract surgery. J Cataract Refract Surg. 28. 826-833
  • Hovding, G, Sjursen, H. (1982). Bacterial contamination of drops and dropper tips of in-use multidose eye drop bottles. Acta Ophthalmol (Copenh). 60. 213-222
  • Kozak, I, Cheng, L, Freeman, WR. (2005). Lidocaine gel anesthesia for intravitreal drug administration. Retina. 25. 994-998
  • Miller, JJ, Scott, IU, Flynn, HW Jr, Smiddy, WE, Newton, J, Miller, D. (2005). Acute-onset endophthalmitis after cataract surger y (2000-2004): incidence, clinical settings, and visual acuity outcomes after treatment. Am J Ophthalmol. 139. 983-987
  • Ferguson, AW, Scott, JA, McGavigan, J. (2003). Comparison of 5% povidone iodine solution against 1% povidone-iodine solution in preoperative cataract surgery antisepsis: a prospective randomised double blind study. Br J Ophthalmol. 87. 163-167
  • Speaker, MG, Menikoff, JA. (1991). Prophylaxis of endophthalmitis with topical povidone-iodine. Ophthalmology. 98. 1769-1775
  • Miño de Kaspar, H, Chang, RT, Singh, K, Egbert, PR, Blumenkranz, MS, Ta, CN. (2005). Prospective Randomized Comparison of 2 Different Methods of 5% Povidone-Iodine Applications for Anterior Segment Intraocular Surgery. Arch Ophthalmol. 123. 161-165
  • Isenberg, S, Apt, L, Yoshimori, R, Khwarg, S. (1985). Chemical preparation of the eye in ophthalmic surgery IV: comparison of povidone-iodine on the conjunctiva with a prophylactic antibiotic. Arch Ophthalmol. 103. 1340-1342
  • Grimes, S, Mein, C, Trevino, S. (1991). Preoperative antibiotic and povidone-iodine preparation of the eye. Ann Ophthalmol. 23. 263-266
  • Snyder-Perimutter, L, Katz, HR, Melia, M. (2000). Effect of topical ciprofloxacin 0.3% and ofloxacin 0.3% on the reduction of bacterial flora on the human conjunctiva. J Cataract Refract Surg. 26. 1620-1625
  • Ta, CN, Egbert, PR, Singh, K, Shriver, EM, Blumenkranz, MS, Miño De Kaspar, H. (2002). Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 109. 2036-2041
  • Osher, RH, Amdahl, LD, Cheetham, JK. (1994). Antimicrobial efficacy and aqueous humor concentration of preoperative and postoperative topical trimethoprim/polymyxin B sulfate versus tobramycin. J Cataract Refract Surg. 20. 3-8
  • Deramo, VA, Lai, JC, Fastenberg, DM, Udell, IJ. (2006). Acute endophthalmitis in eyes treated prophylactically with gatifloxacin and moxifloxacin. Am J Ophthalmol. 142. 721-725
  • Miller, D, Flynn, PM, Scott, IU, Alfonso, EC, Flynn, HW Jr. (2006). In vitro fluoroquinolone resistance in staphylococcal endophthalmitis isolates. Arch Ophthalmol. 124. 479-483
  • Bucci, FA, Amico, LM, Guerino, A, Evans, R. (2003). The effect of preop lid scrubs and levofloxacin on eyelid and conjunctival cultures prior to cataract surgery. Invest Ophthalmol Vis Sci. 44.
Fuente de los datos: Dialnet